Clinical Trials
8 trialsNCT01552434 2026-05-15
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06865664 2026-03-16
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT03009058 2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2 Terminated
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT01063075 2019-09-26
A Study in Advanced Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT01099358 2019-09-26
Study in Advanced Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT00622674 2017-12-02
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00148109 2013-01-24
Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas
University of Michigan Rogel Cancer Center
Phase 2 Completed